SR ONE CAPITAL MANAGEMENT, LP
CIK: 0001910264Latest portfolio: $706.4M · Q4 2025
Holdings
13
Total Value
$706.4M
New Positions
1
Closed Positions
0
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | ZBIOZenas BioPharma, Inc | 5,037,854 | $182.9M | 25.90% | +126K | |
| 2 | ACLXArcellx, Inc. | 2,346,630 | $153.0M | 21.66% | — | |
| 3 | CRSPCRISPR Therapeutics AG | 2,038,763 | $106.9M | 15.14% | — | |
| 4 | DSGNDesign Therapeutics, Inc. | 6,526,476 | $61.2M | 8.67% | — | |
| 5 | MLYSMineralys Therapeutics Inc. | 1,563,966 | $56.8M | 8.03% | -549,967 | |
| 6 | SPRYARS Pharmaceuticals, Inc. | 4,012,903 | $46.8M | 6.62% | — | |
| 7 | ORICORIC Pharmaceuticals, Inc. | 4,514,929 | $37.8M | 5.34% | — | |
| 8 | ALMSAlumis Inc. | 1,959,896 | $19.1M | 2.71% | — | |
| 9 | ORKAOruka Therapeutics, Inc | 430,330 | $13.0M | 1.85% | — | |
| 10 | OCSOculis Holding AG | 641,022 | $12.8M | 1.81% | +319K | |
| 11 | ENGNenGene Holdings Inc. | 747,750 | $6.8M | 0.96% | — | |
| 12 | NKTXNkarta, Inc. | 3,333,333 | $6.2M | 0.87% | — | |
| 13 | RAREUltragenyx Pharmaceutical Inc. | 137,753 | $3.2M | 0.45% | NEW |
Quarterly Changes
New Positions
- RARENEW$3.2M
Closed Positions
No closed positions this quarter
Sector Breakdown
Healthcare100.0% ($1.829241530001069e+55T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 12, 2026 | $706.4M | 13 |
| Q3 2025 | Nov 12, 2025 | $691.4B | 12 |
| Q2 2025 | Aug 14, 2025 | $461.4B | 13 |
| Q1 2025 | May 13, 2025 | $389.3B | 12 |
| Q4 2024 | Feb 13, 2025 | $410.1B | 11 |
| Q3 2024 | Nov 13, 2024 | $498.7B | 11 |
| Q2 2024 | Aug 13, 2024 | $319.4B | 9 |
| Q1 2024 | May 13, 2024 | $364.1B | 6 |
| Q4 2023 | Feb 12, 2024 | $238.2B | 5 |
| Q3 2023 | Nov 13, 2023 | $195.1B | 6 |
| Q2 2023 | Aug 10, 2023 | $231.9B | 6 |
| Q1 2023 | May 9, 2023 | $240.4B | 5 |
| Q4 2022 | Feb 8, 2023 | $273.9B | 5 |
| Q3 2022 | Nov 8, 2022 | $218.7M | 4 |
| Q2 2022 | Aug 2, 2022 | $204.3M | 4 |
| Q1 2022 | May 10, 2022 | $195.3M | 3 |
| Q4 2021 | Feb 14, 2022 | $176.9M | 2 |
Fund Information
SR ONE CAPITAL MANAGEMENT, LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $706.4M across 13 holdings. The largest position is Zenas BioPharma, Inc (ZBIO), representing 25.9% of the portfolio. Compared to the previous quarter, the fund opened 1 new positions and closed 0 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.